Literature DB >> 32039868

Cognitive impairment, clinical symptoms and functional disability in patients emerging from the minimally conscious state.

Yelena G Bodien1,2, Geraldine Martens1,3, Joseph Ostrow1, Kristen Sheau1, Joseph T Giacino1.   

Abstract

BACKGROUND: Although emergence from the minimally conscious state (eMCS) is associated with symptoms including disorientation, memory and attention impairment, restlessness, and significant functional disability, the neurobehavioral profile of eMCS has not been empirically characterized.
OBJECTIVE: Determine degree of cognitive impairment, presence of clinical symptoms and functional disability at time eMCS in patients with traumatic and non-traumatic brain injury (TBI, nTBI).
METHODS: Retrospective observational study of 169 adults (median [interquartile range] age: 51 [29, 62] years; male: 116; TBI: 103) who emerged from MCS based on the Coma Recovery Scale-Revised while in an inpatient Disorders of Consciousness program. Outcome measures include the Confusion Assessment Protocol (CAP) and Disability Rating Scale (DRS).
RESULTS: CAP administration was attempted in 54 subjects. Twenty-eight subjects had valid scores on all CAP items, with a median [interquartile range] of 4 [3-5] symptoms of confusion. Scores in 93% of this subsample were consistent with an acute confusional state. The most common symptoms were cognitive impairment (98% of subjects), disorientation (93%), and agitation (69%). The median DRS score upon emergence from MCS was 14.5 [13, 16], indicating severe disability (n = 140).
CONCLUSIONS: eMCS is associated with an acute confusional state and severe disability. This finding may inform the lower boundary of confusion as well as approach to treatment and caregiver education.

Entities:  

Keywords:  Brain injury; confusion; consciousness; traumatic brain injury

Mesh:

Year:  2020        PMID: 32039868     DOI: 10.3233/NRE-192860

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  7 in total

Review 1.  Prognostication, Ethical Issues, and Palliative Care in Disorders of Consciousness.

Authors:  Adeline L Goss; Claire J Creutzfeldt
Journal:  Neurol Clin       Date:  2022-02       Impact factor: 3.806

2.  Should Consistent Command-Following Be Added to the Criteria for Emergence From the Minimally Conscious State?

Authors:  Katherine Golden; Kimberly S Erler; John Wong; Joseph T Giacino; Yelena G Bodien
Journal:  Arch Phys Med Rehabil       Date:  2022-04-06       Impact factor: 4.060

Review 3.  Update on neuroimaging in disorders of consciousness.

Authors:  Leandro R D Sanz; Aurore Thibaut; Brian L Edlow; Steven Laureys; Olivia Gosseries
Journal:  Curr Opin Neurol       Date:  2021-08-01       Impact factor: 6.283

4.  Application of High-Tech Solution for Memory Assessment in Patients With Disorders of Consciousness.

Authors:  Katarzyna Kujawa; Alina Żurek; Agata Gorączko; Grzegorz Zurek
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.003

5.  Is frontoparietal electroencephalogram activity related to the level of functional disability in patients emerging from a minimally conscious state? A preliminary study.

Authors:  Wanchun Wu; Chengwei Xu; Xiyan Huang; Qiuyi Xiao; Xiaochun Zheng; Haili Zhong; Qimei Liang; Qiuyou Xie
Journal:  Front Hum Neurosci       Date:  2022-09-29       Impact factor: 3.473

6.  The neuroethics of disorders of consciousness: a brief history of evolving ideas.

Authors:  Michael J Young; Yelena G Bodien; Joseph T Giacino; Joseph J Fins; Robert D Truog; Leigh R Hochberg; Brian L Edlow
Journal:  Brain       Date:  2021-12-16       Impact factor: 13.501

7.  Brain Injury Functional Outcome Measure (BI-FOM): A Single Instrument Capturing the Range of Recovery in Moderate-Severe Traumatic Brain Injury.

Authors:  John Whyte; Joseph T Giacino; Allen W Heinemann; Yelena Bodien; Tessa Hart; Mark Sherer; Gale G Whiteneck; David Mellick; Flora M Hammond; Patrick Semik; Amy Rosenbaum; Risa Nakase Richardson
Journal:  Arch Phys Med Rehabil       Date:  2020-10-03       Impact factor: 4.060

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.